Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Last updated: March 14, 2024
Sponsor: Emergent BioSolutions
Overall Status: Terminated

Phase

3

Condition

Healthy Volunteers

Hepatitis B

Hepatitis

Treatment

hepatitis B vaccine

Clinical Study ID

NCT01311674
HB-012
  • Ages 20-55
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Hepatitis B Virus Antibody Booster Program

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Age 20-55 years.
  • Naïve or previously hepatitis B-vaccinated males or females.
  • Normal and healthy as determined by medical history, physical exam, vital signs andclinical laboratory tests
  • Subject must meet all required/recommended subject suitability criteria that pertainto normal source plasma donors with the following exception:
  • Subjects who previously tested positive for HBsAg may be accepted into the anti- HBsprogram provided they now test negative and meet all other normal donor suitabilitycriteria.
  • Written informed consent.

Exclusion

Exclusion Criteria:

  • Subjects who have received a hepatitis B vaccination in the previous six months.
  • History of hypersensitivity to yeast or any components of the Engerix-B® vaccine
  • History of hypersensitivity to any hepatitis B-containing vaccine.
  • Use of any investigational product within the past 30 days or during the course of thestudy.
  • Use of steroids or immunosuppressives during the study period.
  • Received immunosuppressive therapy (including systemic steroids) within 30 days beforestudy entry
  • Subjects who have received cytotoxic therapy (in the previous 5 years prior to studyentry)
  • Received parenteral immune globulin products or blood products within 3 months beforestudy entry with the following exceptions:
  • RhoGAM (or equivalent anti-D immune globulin) within 6 weeks before study entry;
  • Pertussis immune globulin: no exclusion
  • Received parenteral immune globulin products or blood products (within 3 months beforestudy entry)
  • Past, present, or suspected IV drug use
  • Positive HIV, HBV* or HCV test result (*except as described above in InclusionCriteria)
  • Autoimmune disease (such as, but not limited to demyelinating disease)
  • Subjects with cancer, heart disease (including hospitalization for myocardialinfarction, arrhythmia, syncope, congestive heart failure), uncontrolled hypertension,uncontrolled insulin-dependent diabetes mellitus, seizures, kidney disease
  • Severely or morbidly obese, or higher obesity classification, which corresponds to BMIof 35 or higher
  • Pregnancy or lactation.

Study Design

Total Participants: 141
Treatment Group(s): 1
Primary Treatment: hepatitis B vaccine
Phase: 3
Study Start date:
September 01, 2009
Estimated Completion Date:
March 11, 2011

Study Description

The purpose of this study is to vaccinate plasmapheresis donors for collection of high titer plasma to be used in the manufacture of Hepatitis B Immune Globulin (HBIG).

Connect with a study center

  • Cangene Plasma Resources, Mid-Florida

    Altamonte Springs, Florida 32701
    United States

    Site Not Available

  • Cangene Plasma Resources, Frederick

    Frederick, Maryland 21702
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.